BioHarvest Sciences Inc. Common Stock Total Liabilities
BioHarvest Sciences Inc. Common Stock total liabilities. Based on the latest financial reports, BioHarvest Sciences Inc. Common Stock (BHST) has total liabilities worth $24.80 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of BioHarvest Sciences Inc. Common Stock to evaluate the company's liquid asset resilience ratio.
Total Liabilities of BioHarvest Sciences Inc. Common Stock (2013–2025)
Total liabilities of BioHarvest Sciences Inc. Common Stock from 2013 to 2025. This chart illustrates how BioHarvest Sciences Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
BioHarvest Sciences Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of BioHarvest Sciences Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pancontinental Oil & Gas N.L. R
F:PUB
|
Germany | €823.28K |
|
Senheng New Retail Bhd
KLSE:5305
|
Malaysia | RM304.44 Million |
|
Nam Hwa Construction Co.Ltd
KQ:091590
|
Korea | ₩22.72 Billion |
|
Natura City Developments Tbk PT
JK:CITY
|
Indonesia | Rp180.80 Billion |
|
Webstep ASA
OL:WSTEP
|
Norway | Nkr262.30 Million |
|
Gol Linhas Aéreas Inteligentes S.A
NYSE:GOLLQ
|
USA | $45.83 Billion |
|
Comtech Telecommunications Corp
NASDAQ:CMTL
|
USA | $430.21 Million |
|
Eduspec Holdings Bhd
KLSE:0107
|
Malaysia | RM32.07 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down BioHarvest Sciences Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of BioHarvest Sciences Inc. Common Stock.
Liquidity & Leverage Metrics
BioHarvest Sciences Inc. Common Stock Total Liabilities Ratios Explained
BioHarvest Sciences Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioHarvest Sciences Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioHarvest Sciences Inc. Common Stock (2013–2025)
The table below shows the annual total liabilities of BioHarvest Sciences Inc. Common Stock from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $22.22 Million | -6.14% |
| 2024-12-31 | $23.67 Million | -20.71% |
| 2023-12-31 | $29.86 Million | +94.85% |
| 2022-12-31 | $15.32 Million | +108.38% |
| 2021-12-31 | $7.35 Million | -3.24% |
| 2020-12-31 | $7.60 Million | -73.79% |
| 2019-12-31 | $28.99 Million | +1943.37% |
| 2018-12-31 | $1.42 Million | +5022.33% |
| 2017-12-31 | $27.70K | -77.14% |
| 2016-12-31 | $121.17K | +113.13% |
| 2015-12-31 | $56.86K | +9.08% |
| 2014-12-31 | $52.12K | +570.11% |
| 2013-12-31 | $7.78K | -- |
About BioHarvest Sciences Inc. Common Stock
BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science-based health and w… Read more